{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:16:03Z","timestamp":1792556163469,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.eprac.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:05:25Z","timestamp":1711649125000},"page":"584-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Endocrinopathies Associated With Immune Checkpoint Inhibitor Use"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4500-8546","authenticated-orcid":false,"given":"Anupam","family":"Kotwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randol","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Kikani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Thosani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Goldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afreen","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eprac.2024.03.023_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr Pract"},{"issue":"36","key":"10.1016\/j.eprac.2024.03.023_bib2","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.eprac.2024.03.023_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib9","article-title":"Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis","volume":"7","author":"Quandt","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib10","first-page":"939","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J\u00a0Invest Med"},{"issue":"18","key":"10.1016\/j.eprac.2024.03.023_bib11","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eprac.2024.03.023_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11102-019-00978-4","article-title":"Ipilimumab-induced hypophysitis, a single academic center experience","volume":"22","author":"Snyders","year":"2019","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.eprac.2024.03.023_bib13","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis\u2014a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"issue":"230","key":"10.1016\/j.eprac.2024.03.023_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.03.023_bib16","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.eprac.2024.03.023_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/OP.23.00023","article-title":"Endocrine dysfunction from immune checkpoint inhibitors: pearls and pitfalls in evaluation and management","volume":"19","author":"Kotwal","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib18","article-title":"The changing epidemiology of adrenal insufficiency: iatrogenic factors predominate","volume":"7","author":"Rushworth","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib19","doi-asserted-by":"crossref","first-page":"e3107","DOI":"10.1210\/clinem\/dgac359","article-title":"The changing face of drug-induced adrenal insufficiency in the food and drug administration adverse event reporting system","volume":"107","author":"Raschi","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"De Sousa","year":"2018","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.eprac.2024.03.023_bib23","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/er.2018-00166","article-title":"Growth hormone\u2019s links to cancer","volume":"40","author":"Boguszewski","year":"2018","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.eprac.2024.03.023_bib25","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ando.2023.03.014","article-title":"Pituitary and adrenal disorders induced by immune checkpoint inhibitors","volume":"84","author":"Albarel","year":"2023","journal-title":"Ann Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s40425-019-0729-3","article-title":"Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis","volume":"7","author":"Thapi","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2024.03.023_bib32","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib34","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system","volume":"27","author":"Lu","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"issue":"10","key":"10.1016\/j.eprac.2024.03.023_bib38","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"696","key":"10.1016\/j.eprac.2024.03.023_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"6","key":"10.1016\/j.eprac.2024.03.023_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors","volume":"36","author":"Iwama","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib43","first-page":"2140","article-title":"Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib44","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1210\/clinem\/dgab829","article-title":"Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline","volume":"107","author":"Iwama","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.03.023_bib45","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor\u2013associated thyroid immune\u2013related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2024.03.023_bib47","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2024.03.023_bib48","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib49","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib51","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.eprac.2024.03.023_bib52","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.3390\/cancers15245803","article-title":"Increased thyroidal activity on routine FDG-PET\/CT after combination immune checkpoint inhibition: temporal associations with clinical and biochemical thyroiditis","volume":"15","author":"Galligan","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib54","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/cancers13081944","article-title":"Graves' disease during immune checkpoint inhibitor therapy (A case series and literature review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.eprac.2024.03.023_bib55","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.eprac.2024.03.023_bib56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2024.03.023_bib58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.eprac.2024.03.023_bib59","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.03.023_bib60","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor\u2013associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib61","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"6","key":"10.1016\/j.eprac.2024.03.023_bib64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2217\/imt-2021-0316","article-title":"Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center","volume":"15","author":"Jeun","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.eprac.2024.03.023_bib65","article-title":"PD-1 pathway-mediated regulation of islet-specific CD4(+) T cell subsets in autoimmune diabetes","volume":"3","author":"Martinov","year":"2016","journal-title":"Immunoendocrinology (Houst)"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib66","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/db12-1475","article-title":"PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes","volume":"62","author":"Pauken","year":"2013","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","article-title":"Mechanisms of PDL1-mediated regulation of autoimmune diabetes","volume":"125","author":"Guleria","year":"2007","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089561","article-title":"Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes","volume":"9","author":"Kochupurakkal","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib70","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","article-title":"Interferon-gamma drives programmed death-ligand 1 expression on islet beta cells to limit T cell function during autoimmune diabetes","volume":"8","author":"Osum","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cmet.2017.01.005","article-title":"Beta cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice","volume":"25","author":"Rui","year":"2017","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.03.023_bib72","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.eprac.2024.03.023_bib74","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"10035","key":"10.1016\/j.eprac.2024.03.023_bib75","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","article-title":"Genetic risk factors for type 1 diabetes","volume":"387","author":"Pociot","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.03.023_bib76","article-title":"Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China. Original Research","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jdi.12119","article-title":"Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the committee of Japan Diabetes Society on the Research of Fulminant and Acute-Onset Type 1 Diabetes Mellitus","volume":"5","author":"Kawasaki","year":"2014","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.eprac.2024.03.023_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229823","article-title":"A\u00a0single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Original Research","volume":"14","author":"Marsiglio","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.eprac.2024.03.023_bib79","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.03.023_bib80","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib81","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib82","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/OP.20.00781","article-title":"Adrenal insufficiency from immune checkpoint inhibitors masquerading as sepsis","volume":"17","author":"Abdallah","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.03.023_bib84","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib86","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A\u00a0case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"2","key":"10.1016\/j.eprac.2024.03.023_bib87","article-title":"Marked hypoleptinemia precedes overt fat loss in immune checkpoint inhibitor-induced acquired generalized lipodystrophy","volume":"1","author":"Dhanasekaran","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.eprac.2024.03.023_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2024.03.023_bib89","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/OP.22.00469","article-title":"Minding the bathwater: fertility and reproductive toxicity in the age of immuno-oncology","volume":"18","author":"Kim","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eprac.2024.03.023_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.eprac.2024.03.023_bib91","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.eprac.2024.03.023_bib92","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eprac.2021.09.015","article-title":"Lessons learned from establishing an oncoendocrinology clinic","volume":"28","author":"Cheung","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2024.03.023_bib93","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","article-title":"A\u00a0multidisciplinary toxicity team for cancer immunotherapy-related adverse events","volume":"17","author":"Naidoo","year":"2019","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.eprac.2024.03.023_bib94","article-title":"Dearth of ICD codes for complications of immune checkpoint inhibitors impedes clinical care and research","volume":"7","author":"Cheung","year":"2023","journal-title":"J\u00a0Endocr Soc"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:05:21Z","timestamp":1717434321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2400106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1530891X2400106X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.03.023","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrinopathies Associated With Immune Checkpoint Inhibitor Use","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}